register

News & Trends - Pharmaceuticals

PBS changes to opioids a win for palliative care, according to AMA

Health Industry Hub | October 1, 2020 |

Pharma News: The Australian Medical Association welcomes much needed improvements to the Pharmaceutical Benefits Scheme (PBS) listings for opioids, which will clarify their important role in alleviating suffering for palliative care patients.

AMA President Dr Omar Khorshid said the Association supported important reforms to reduce the inappropriate use of opioids in Australia.

“However, the original PBS changes implemented on 1 June 2020 caused significant confusion and concern from prescribers and their patients,” Dr Khorshid said.

“The changes unintentionally made accessing opioids from prescribers more difficult for palliative care patients with a legitimate clinical need.

“This was particularly difficult for non-cancer palliative care patients.

“Opioids are clinically necessary in many circumstances to relieve suffering from pain and breathlessness experienced by palliative care patients.

“Prescribers were also faced with additional administrative burden when requesting PBS approval for opioids.”

The AMA has been advocating to the Department of Health and the Therapeutic Goods Administration, providing feedback from AMA members on the 1 June 2020 changes.

“The Pharmaceutical Benefits Advisory Committee (PBAC) has reflected this feedback in the 1 October 2020 PBS listing changes, so it’s pleasing that the vital advocacy work of the AMA has been heeded,” Dr Khorshid said.

“Patients will be exempt from the 12-month pain management review by a second doctor or palliative care nurse practitioner if their clinical condition makes the review not possible.

“This is an important change for palliative care patients who may be too unwell for this to occur.”

The AMA President thanked Palliative Care Australia for their work in this space and their ongoing advocacy for palliative care and said the AMA would continue to work with the government and other stakeholders to improve communication on opioid reforms.

“Current clinical guidelines do not recommend opioids for the long-term treatment of chronic non-cancer pain,” Dr Khorshid said.

“Almost 150 hospitalisations, 14 emergency department presentations, and three deaths every day in Australia are caused by issues linked to inappropriate opioid use and this is a set of numbers we need to continually focus on improving.”


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.